QHSLab Inc.
QHSLab, Inc. is a digital health company focused on enabling independent primary care practices to identify, document, and manage underdiagnosed and undertreated behavioral health conditions (behavioral vital signs) through workflow-integrated digital screening and non-face-to-face follow-up care. Our platform is designed to support population-based screening, patient education, and follow-up c…
$0.31
-$0.15 (-32.61%)
Price from 3 days ago
Operating margin is thin at 4.88%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 26.3%, still solid. Margins contracted 4.8pp, which offsets some of the top-line progress.
ROIC dropped from 17.59% to 11.64%, capital efficiency is deteriorating. Operating margin contracted 4.8pp YoY, cost discipline may be slipping.
10.3x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$3M
▲ +26.3% YoY
Net Income (TTM)
$524K
▲ +276.4% YoY
Op. Margin
2.74%
▼ -4.8pp YoY
ROIC
5.40%
▼ -6.0pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$107K
▲ +25.1% YoY
Net Debt
-$317K
Net Cash Position
Cash & Equiv.
$317K
5Y CAGR: +84.9%
Continue Research
SourceComputed from the 10-Q filed 12 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 14 Oct 2026. How this is calculated.
Price from market data, last close as of 15 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is QHSLab (USAQ) overvalued?
At a P/E of 10.3, QHSLab (USAQ)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, QHSLab scores 49/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is QHSLab a high-quality business?+
QHSLab scores 49 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 2.7% operating margin and a 5.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is QHSLab a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh USAQ's valuation and scores 49/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Surgical & Medical Instruments & Apparatus
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.